{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-045714","form_type":"8-K","ticker":"GTBP","cik":"0000109657","company_name":"GT Biopharma, Inc.","filed_at":"2023-12-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.210579+00:00","generated_at":"2026-06-07T08:46:30.338855+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"GT Biopharma shareholders approve reverse stock split authorization at ratio of 1:5 to 1:30","bullets":["Special meeting on Dec 18, 2023; 58.13% of outstanding shares voted.","Proposal passed with 20.3M for, 3.8M against, 17k abstain.","Board has discretion to set final ratio within 1-for-5 to 1-for-30 range.","Reverse split authorization is part of charter amendment to be announced publicly."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-045714","json":"https://secwatch.observer/filing/0001493152-23-045714.json","markdown":"https://secwatch.observer/filing/0001493152-23-045714.md","text":"https://secwatch.observer/filing/0001493152-23-045714.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/109657/000149315223045714/0001493152-23-045714-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/109657/000149315223045714/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T08:46:30.338855+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"be05419497dad2ac4979b96ef22aa82fa4492bee","claim":"GT Biopharma, Inc. shareholders approved Reverse stock split at ratio between 1-for-5 to 1-for-30 at the 2023-12-18 meeting.","evidence_excerpt":"Proposal to approve an amendment to the Registrant’s second restated certificate of incorporation, as amended, to effect a reverse stock split with respect to the Registrant’s issued and outstanding common stock, par value $0.001 per share, at a ratio between 1-for-5 to 1-for-30, or the Range, with the ratio within such Range to be determined at the discretion of the Board without further approval or authorization of the Registrant’s stockholders and included in a public announcement.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/109657/000149315223045714/0001493152-23-045714-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-12-18"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}